SymBio Pharmaceuticals Limited

SymBio Pharmaceuticals provides the and development, manufacturing and sales of pharmaceuticals and other related operations in Japan and globally. It offers SyB V-1901, an antiviral drug for post-transplant infections, blood cancers and solid tumors, and neurodegenerative diseases.

Its portfolio also includes SyB L-1701, an RTD liquid formulation, and SyB L-1702, an RI administration under the TREAKISYM name. The company was incorporated in 2005 and is based in Minato, Japan.